One of 5 listed pharmas spending more than 10% of their sales into R&D

Listed pharmaceutical companies have been criticized to pay no attention in making investment into R&D.

Yakup Shinmoon(www.yakup.com) analyzed KOSPI and KOSDAQ listed pharmaceutical companies’ 2018 first half business report, and the analysis result showed that they had an 8.04% R&D investment ratio to sales.

Although the ratio is similar to the end of the last year’s 8.02%, it is still decre...